Biomarkers Conference, on rare and polyfactorial and neglected deseases

Biomarkers Conference, on rare and polyfactorial and neglected deseases
10 décembre 2009, Paris, France

Genopole est Partenaire info veille biotech
Clic !
Update your knowledge in biomarkers clinical development in very focused and specific areas of biomarkers, namely in genetic rare diseases (neurologic and muscle diseases), in two highly frequent multi-factorial genetic diseases (metabolism/diabetes and rheumatology) and in highly frequent but neglected diseases (malaria and tuberculosis) which occur mainly in the developing and poor world. The latest development of new technical and computational tools will be presented including the use or embryonic stem cells for following up rare monogenic diseases. The incidence of the development of biomarker use on health economy and health policy will be addressed before closing this conference.
Topics:
- Comprehensive coverage of biomarkers in :
    Genetic rare diseases
    Genetic polyfactorial diseases
    Neglected diseases
- New technical and computational tools for biomarkers analysis
- How health policy may change after biomarker analysis implementation
Invited speakers:
Alessandra Cervino, Vice president Biostatistics & Bioinformatics TCLand Expression
David Cumming, Professor in electronic engineering and group leader, Electronics & Electrical Engineering, University of Glasgow
Bruno Domon, Head of the mass spectrometry Lab and biomarker program at the Institute of Molecular Systems Biology, ETH Zurich
Isabelle Durand-Zaleski, Responsable de l’unité évaluation-études à l’Hôpital Henri Mondor, Directeur Scientifique à l’Institut d’étude des politiques de santé,Groupe hospitalier Albert Chenevier Henri Mondor
Philippe Froguel, Professor and Head of Section of Genomic Medicine, Hammersmith Hospital, Imperial College London
Head of the Unité mixte de Recherche CNRS 8090 Lille 2, Institut Pasteur Lille
Alain Huriez, Chairman & CEO, TCLand Expression
Pierre Miossec, Professor, Department of Immunology and Rheumatology, University of Lyon & E. Herriot Hospital
Piero L. Olliaro, Leader, chemotherapy for Neglected Tropical Diseases, World Health Organization
Marc Peschanski, Director of research, Chief Scientific Officer of  the Institute for Stem cell Therapy and Exploration of Monogenic Diseases
Alessandro Quattrone, Director of the Center for Integrative Biology, University of Trento
Thomas Voit, Scientific and Medical Director of The Myology Institute & head of the UMRS 974 and 7215 Units
Brenda Wong, , MBBS, MRCP, Child Neurologist, Cincinnati Children's Hospital Medical Center & Associate Professor of Pediatrics and Neurology
Plus d'info